Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Northwestern University Northwestern Memorial Hospital |
---|---|
Information provided by: | Northwestern University |
ClinicalTrials.gov Identifier: | NCT00393185 |
This disease is believed to be due to immune cells, cells which normally protect the body, but are now destroying the bile ducts in the liver. When the ducts are damaged, bile builds up in the liver and damages liver tissue. Over time, the disease can cause cirrhosis and may make the liver stop working. This study is designed to examine whether treating patients with high dose Cyclophosphamide and Fludarabine (drugs which reduce the function of your immune system) and CAMPATH-1H (a protein that kills the immune cells that are thought to be causing PBC), followed by return of blood stem cells that have been previously collected from patient brother or sister will stop or reverse the disease. The purpose of the Cyclophosphamide, Fludarabine and CAMPATH-1H is to decrease immune system. The purpose of the stem cell infusion is to restore blood production, which will be severely impaired by the Cyclophosphamide, Fludarabine and CAMPATH-1H, and to produce a normal immune system that will no longer attack the body.
Condition | Intervention | Phase |
---|---|---|
Primary Biliary Cirrhosis |
Procedure: Non-myeloablative Hematopoietic Stem Cell Transplantation |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Primary Biliary Cirrhosis: A Phase I Study |
Estimated Enrollment: | 10 |
Study Start Date: | January 2006 |
Estimated Study Completion Date: | January 2015 |
Estimated Primary Completion Date: | January 2011 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Patient enrollment
Inclusion Criteria:
And any of the following
Exclusion Criteria:
Poor performance status (ECOG > 2) at the time of entry
2.Serum bilirubin > 4.0 mg/dl
3.Significant end organ damage such as:
Serum creatinine > 2.0 mg/dl
4.HIV positive
5.Uncontrolled diabetes mellitus, or any other illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive treatment
6.Prior history of malignancy except localized basal cell or squamous skin cancer; Other malignancies for which the patient is judged to be cured by local surgical therapy, such as (but not limited to) head and neck cancer, or stage I or II breast cancer will be considered on an individual basis
7.Positive pregnancy test, inability or unable to pursue effective means of birth control, failure to willingly accept or comprehend irreversible sterility as a side effect of therapy
8.Psychiatric illness or mental deficiency making compliance with treatment or informed consent impossible
9.Inability to give informed consent
10.Major hematological abnormalities such as platelet count < 100,000/ul or ANC < 1000/ul
11.GI bleed from portal hypertension
12.Portal HTN documented by transvenous portal vein wedge pressure greater than 20 cm H20
13.Ascites that is non-responsive to full-dose diuretics and human albumin infusion
14.Systemic sclerosis
15.AMA positive donor
16.HCV PCR positive or HBSAg positive donor
17.Failure to collect less than 2.0 x 106 CD34 cells/kg from a matched sibling
18.Patient on liver transplant list
Donor enrollment
Inclusion Criteria:
Exclusion criteria:
Contact: Dzemila Spahovic, MD | 312-503-0356 | d-spahovic@northwestern.edu |
United States, Illinois | |
Northwestern University, Feinberg School of Medicine | Recruiting |
Chicago, Illinois, United States, 60611 | |
Principal Investigator: Richard Burt, MD | |
Sub-Investigator: Eric Gershwin, MD | |
Sub-Investigator: Robert Craig, MD |
Principal Investigator: | Richard Burt, MD | Northwestern University |
Responsible Party: | Northwestern University ( Richard Burt, MD ) |
Study ID Numbers: | PBC |
Study First Received: | October 24, 2006 |
Last Updated: | November 6, 2008 |
ClinicalTrials.gov Identifier: | NCT00393185 |
Health Authority: | United States: Food and Drug Administration |
Immunosuppression Primary Biliary Cirrhosis Allogeneic Hematopoietic Stem Cell |
Biliary cirrhosis Liver Diseases Digestive System Diseases Cholestasis, Intrahepatic Bile Duct Diseases Cholestasis |
Fibrosis Biliary Tract Diseases Liver Cirrhosis Primary biliary cirrhosis Liver Cirrhosis, Biliary |
Pathologic Processes |